Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Octreotide LAR in Advanced GI NET
NCT01567488Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Jun 2011
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in gastrointestinal neuroendocrine tumor, sponsored by Spanish Group of Neuroendocrine Tumors. Started Jun 2011; status: completed.
02
Drugs
everolimus
03
Conditions
gastrointestinal neuroendocrine tumor
Beyond the preview
Go deeper on NCT01567488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01567488.